aTYR PHARMA (ATYR) Total Debt Growth (1y) (2015 - 2020)
Powered by 
Analysis
aTYR PHARMA (ATYR) Total Debt Growth (1y) (2015 - 2020) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 208.48 Bn | 194.49 Bn | 7.24 Bn | 6.99% |
| 2 | Gilead Sciences | 186.29 Bn | 183.02 Bn | 6.22 Bn | 3.27% |
| 3 | Vertex Pharmaceuticals | 128.79 Bn | 120.93 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 80.66 Bn | 72.67 Bn | 3.93 Bn | 0.10% |
| 5 | Moderna | 61.46 Bn | 56.32 Bn | 52.00 Mn | - |
| 6 | Argenx Se | 61.28 Bn | 56.10 Bn | 1.37 Bn | - |
| 7 | Alnylam Pharmaceuticals | 32.04 Bn | 28.73 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.84 Bn | 30.56 Bn | 1.96 Bn | 25.75% |
| 9 | Roivant Sciences | 28.74 Bn | 29.43 Bn | 1.16 Mn | - |
| 10 | aTYR PHARMA | 35.31 Mn | -22.30 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2020 | -71.08% |
| Jun 30, 2020 | -59.93% |
| Mar 31, 2020 | -51.75% |
| Dec 31, 2019 | -45.50% |
| Sep 30, 2019 | -40.55% |
| Jun 30, 2019 | -36.53% |
| Mar 31, 2019 | -28.76% |
| Dec 31, 2018 | -18.76% |
| Sep 30, 2018 | 20.76% |
| Jun 30, 2018 | 34.21% |
| Mar 31, 2018 | 108.66% |
| Dec 31, 2017 | 106.89% |
| Sep 30, 2017 | 458.56% |
| Jun 30, 2017 | 317.83% |
| Mar 31, 2017 | 121.47% |
| Dec 31, 2016 | 85.47% |
| Sep 30, 2016 | -55.61% |
| Jun 30, 2016 | -48.21% |
| Mar 31, 2016 | -54.55% |
| Dec 31, 2015 | -49.96% |